VR Logo

Surrozen Inc. (SRZN) download report


Healthcare | Biotechnology & Pharma Research

Surrozen Inc. (SRZN) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration.

IPO Date: 11-Jan-2021

CEO, Pres & Director: Mr. Craig C. Parker M.B.A.

Chief Financial Officer: Mr. Charles Williams

Listing: NASDAQ: SRZN

Country: United States

Headquarters: South San Francisco, CA

Website: https://www.surrozen.com

Key Facts

Market cap: $120.48 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-44.09 Mln

Cash: $92.51 Mln

Total Debt: $7.22 Mln

Insider's Holding: 6.88%

Liquidity: Low

52 Week range: $1.98 - 14.00

Shares outstanding: 35,125,900

Stock Performance

Time Period Surrozen (SRZN) S&P BSE Sensex S&P Small-Cap 600
YTD-48.14-8.71-17.92
1 month20.58-3.11-7.88
3 months0.60-7.30-13.56
1 Year--0.48-17.16
3 Years--10.346.95
5 Years--11.436.30
10 Years--12.1010.29
As on 28-Jun-2022